Cite
HARVARD Citation
Nirogi, R. et al. (n.d.). 0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates. Sleep. p. A57. [Online].